A side-by-side reading of MOTS-c and SS-31 from our profiles: origin, mechanism, studied uses and evidence status. No recommendations — only what the sources say.
Key parameters side by side
Parameter
MOTS-c
SS-31
Category
Longevity
Longevity
Evidence status
Experimental
Approved
Sequence length
16
—
Molecular weight
2174.50 Da
640.80 Da
Longevity
MOTS-c
Experimental
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid mitochondrial-derived peptide encoded in the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by Dr. Pinchas Cohen's laboratory at USC, MOTS-c was the first mitochondrial-encoded peptide shown to have profound metabolic effects — functioning as an exercise mimetic that enhances insulin sensitivity, promotes fat oxidation, and improves metabolic homeostasis.
MOTS-c's discovery expanded the concept of mitochondrial-derived peptides (MDPs) as a new class of signaling molecules. Remarkably, MOTS-c translocates to the nucleus during metabolic stress, directly regulating gene expression — the first example of a mitochondrial-encoded peptide acting as a nuclear transcription regulator. It declines with age, suggesting a role in age-related metabolic dysfunction.
SS-31 (elamipretide, Bendavia, MTP-131) is a mitochondria-targeted tetrapeptide developed at Weill Cornell Medical College that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin — a unique phospholipid essential for electron transport chain complex organization and function. By stabilizing cardiolipin-protein interactions, SS-31 restores efficient mitochondrial electron transport, reduces ROS production, and improves ATP synthesis.
SS-31 has undergone extensive clinical trials for heart failure (EMBRACE trial), mitochondrial myopathy (MMPOWER trials), and Barth syndrome. Its ability to directly target mitochondrial dysfunction addresses a fundamental mechanism underlying aging, neurodegeneration, cardiomyopathy, and metabolic disease.
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid mitochondrial-derived peptide encoded in the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by Dr. Pinchas Cohen's laboratory at USC, MOTS-c was the first mitochondrial-encoded peptide shown to have profound metabolic effects — functioning as an exercise mimetic that enhances insulin sensitivity, promotes fat oxidation, and improves metabolic homeostasis.
MOTS-c's discovery expanded the concept of mitochondrial-derived peptides (MDPs) as a new class of signaling molecules. Remarkably, MOTS-c translocates to the nucleus during metabolic stress, directly regulating gene expression — the first example of a mitochondrial-encoded peptide acting as a nuclear transcription regulator. It declines with age, suggesting a role in age-related metabolic dysfunction.
SS-31 (elamipretide, Bendavia, MTP-131) is a mitochondria-targeted tetrapeptide developed at Weill Cornell Medical College that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin — a unique phospholipid essential for electron transport chain complex organization and function. By stabilizing cardiolipin-protein interactions, SS-31 restores efficient mitochondrial electron transport, reduces ROS production, and improves ATP synthesis.
SS-31 has undergone extensive clinical trials for heart failure (EMBRACE trial), mitochondrial myopathy (MMPOWER trials), and Barth syndrome. Its ability to directly target mitochondrial dysfunction addresses a fundamental mechanism underlying aging, neurodegeneration, cardiomyopathy, and metabolic disease.